Avanir likely win patent case against Impax, says Jefferies After reviewing court transcripts, Jefferies believes Avanir (AVNR) is likely to win its Nuedexta patent trial against Impax (IPXL). The firm says that while the stock is may rally on the patent win, it sees limited upside and keeps a Hold rating on Avanir. Jefferies notes that its $4 price target already assumes full credit for the Nuedexta patent.
Avanir AVP-923 data looks better than expected, says Piper Jaffray Piper Jaffray says the Phase II data Avanir presented for AVP-923 in Alzheimer's agitation at the American Neurological Association Monday was better than expected and could open the door for a billion dollar opportunity. It reiterates an Overweight rating on the stock with a $21 price target.